News

Ascendis Pharma A/S Set to Announce Q3 Earnings Soon

Ascendis Pharma A/S Set to Announce Q3 Earnings Soon

Ascendis Pharma's Anticipated Q3 Earnings Report

Ascendis Pharma A/S (NASDAQ: ASND) is gearing up to release its earnings results for the third quarter. This announcement is eagerly awaited by investors and analysts alike, as it follows a transformative period for the company.

Analysts' Expectations

Market analysts are predicting that Ascendis Pharma will report a quarterly loss of 16 cents per share. This is a significant decrease compared to a loss of $1.72 per share from the same period last year. Furthermore, the estimated revenue for the quarter stands at approximately $210.87 million, which represents a striking increase from the $57.83 million reported a year prior.

Recent Developments in Ascendis Pharma

Recently, Ascendis Pharma took a significant step by submitting a marketing authorization application to the European Medicines Agency for its innovative treatment, TransCon CNP, aimed at helping children with achondroplasia. This could mark a crucial advancement for the company in the pediatric space.

Stock Performance

On a positive note, shares of Ascendis Pharma observed a modest increase, rising by 2.6% to close at $201.16. Such movement can instill confidence among investors, especially as the earnings report approaches.

Insight from Analysts

Several analysts have recently updated their ratings and price targets for Ascendis Pharma. For instance, Raymond James analyst Martin Auster has kicked off coverage with a Strong Buy rating and issued a price target of $271. This is a clear indication of confidence in the stock amidst potential growth.

Further Analyst Ratings

JP Morgan analyst Jessica Fye retains an Overweight rating, raising the price target from $260 to $264, reflecting a strong belief in Ascendis' growth trajectory. Additionally, B of A Securities' Tazeen Ahmad has maintained a Buy rating while boosting the price target from $227 to $230, indicating a positive outlook for the company.

Looking Ahead

As analysts continue to revise their forecasts favorably, investors are keen to see how these expectations align with the earnings report. Citigroup's David Lebowitz also raised the price target from $243 to $290, showcasing a sustained interest in Ascendis Pharma's future.

Considering Investment?

For those contemplating an investment in ASND stock, the insights from analysts provide a compelling perspective. With multiple analysts backing the stock with strong ratings, the forthcoming earnings report could influence market sentiments substantially.

Frequently Asked Questions

What are analysts predicting for Ascendis Pharma's Q3 earnings?

Analysts expect a quarterly loss of 16 cents per share, significantly better than last year's loss of $1.72.

How much revenue is Ascendis Pharma expected to generate?

The consensus estimate for revenue is approximately $210.87 million, up from $57.83 million a year ago.

What recent developments has Ascendis Pharma made?

They recently submitted a marketing authorization application for TransCon CNP for children with achondroplasia.

What did Ascendis Pharma's stock close at recently?

The stock closed at $201.16, reflecting a 2.6% increase.

What are the price targets given by analysts for ASND stock?

Analysts have set price targets ranging from $230 to $290, indicating substantial growth expectations.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

LLCP Backs Empower in UK Infrastructure Services Push

Updated Category News Views 71

A majority cheque has landed in a business built around unglamorous work that cannot be wished away: keeping mechanical and electrical systems installed, refurbished and maintained. On November 18, LLCP said it completed a majority investment in London-headquartered Empower Technical Services alongside chief executive Nicholas Manning, co-founders Florian Kronawitter and...

Continue Reading
Workday GO for Financials Targets the Messy Middle

Updated Category News Views 160

Spreadsheets rarely die gracefully; they get buried under approvals, reconciliations, and the frantic scavenger hunt before an audit. Workday is aiming straight at that unpleasant moment with Workday GO for Financials, announced November 18 at Workday Rising EMEA in Barcelona. The pitch is not terribly romantic, thank goodness. It is a simpler way for growing companies to...

Continue Reading
Epsium's Inventory Pile Looms Over Weak First Half

Updated Category News Views 18

A warehouse full of bottles is not a balance-sheet fortress when buyers are backing away. Epsium Enterprise’s first-half 2026 report is a rough read: revenue collapsed 51.8% to $1.47 million, gross profit fell to $175,353, and cash slid to $612,761 at June 30. This is not a subtle slowdown. Macau’s premium Chinese-liquor market has been weak on both demand and...

Continue Reading
Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 209

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
Clorox Boosts Payout With Steady $1.25 Dividend

Updated Category News Views 221

Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...

Continue Reading
Novo and nference Push Whole-Body Data Into Research

Updated Category News Views 26

Cardiometabolic medicine has spent too long staring at single numbers while the rest of the body keeps waving its arms. Novo Nordisk’s newly announced collaboration with nference is an attempt to widen that lens, combining Novo’s clinical-trial research with nference’s AI technology and federated healthcare data network. The target is not small: obesity, diabetes,...

Continue Reading
Disney Springs Hotel Rates Test Holiday Demand Depth

Updated Category News Views 112

A $145 room rate is the sort of holiday bait that gets my attention before the fake snow does. Disney Springs Resort Area Hotels are extending a seasonal offer for stays through Dec. 18, 2026, with bookings open only through Nov. 20. That is a very narrow selling window, and it tells you plenty: these seven independent hotels want to fill rooms during a lucrative but...

Continue Reading
Lummus-Versalis Deal Adds Nine Elastomer Technologies

Updated Category News Views 93

Nine elastomer technologies do not make a flashy headline, yet this is the sort of chemical-industry move that can matter long after the applause dies down. Lummus Technology and Versalis have expanded their partnership to cover nine elastomer technologies. That is the disclosed fact, and it is meaningful on its own. The release does not lay out contract value, duration,...

Continue Reading
Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 173

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading
Stardock Fences 7 Targets Messy Windows Desktops Everywhere

Updated Category News Views 77

A cluttered Windows desktop is a tiny tax on attention, and Stardock has spent three decades selling people a way around it. Fences 7, released November 18, 2026, is the latest swing: a Windows 11-focused update that combines cosmetic polish with a genuinely practical privacy feature. This is not grand enterprise software, and nobody should pretend a $10 desktop utility...

Continue Reading

Top 5 Most Recently Viewed Articles

US Technology Restrictions: A Temporary Pause Ahead of Talks

Updated Category News Views 251

US Pauses Technology Restrictions on China As crucial diplomatic discussions approach, the US administration has put several significant technology restrictions on hold, affecting China. This suspension comes as a preparation for an important meeting between Donald Trump and Xi Jinping, anticipated to pave the way for enhanced dialogue on trade and technological...

Continue Reading
Vireo Growth Inc. Secures $75 Million Financing for Expansion

Updated Category News Views 347

Vireo Growth Inc. Secures $75 Million Financing for Expansion — $75 million equity financing at $0.625 per Vireo share will result in combined new entity having an industry-leading balance sheet — — Transactions would expand Vireo’s operating footprint to 7 states, 9 cultivation facilities, and 48 dispensaries — — Combined new entity would have an estimated...

Continue Reading
BELFOR Franchise Group Brands Shine on Top Franchise List

Updated Category News Views 290

BELFOR Franchise Group Brands Recognized for Excellence Six distinct brands under the BELFOR Franchise Group umbrella have made the prestigious Franchise Times Top 400 list for 2025. These brands—Chem-Dry, HOODZ, 1-800 WATER DAMAGE, N-Hance, Blue Kangaroo Packoutz, and DUCTZ—stand out for their outstanding national systemwide sales, reflecting the strength and...

Continue Reading
BrainCo Leads BCI Revolution: A Game-Changer Debuts

Updated Category News Views 66

The Frontier of Thought-Controlled Robotics The 2026 World Artificial Intelligence Conference in Shanghai saw BrainCo unleash what felt like a scene straight outta a sci-fi flick. You had a wild display of mind-boggling tech where a person thinks about grabbing a cup, and blam, a robotic arm does it. No joystick, no commands, just pure brainpower in action. This isn't...

Continue Reading
Revolutionizing Data Center Management with AI and Imaging

Updated Category News Views 223

Unleashing Efficiency in Data Center Management In an era where data center operations are continually evolving, the collaboration between AMI and Cupola360 represents a significant leap forward. By merging AMI's Data Center Manager (DCM) with Cupola360's innovative panoramic imaging technology, both companies are setting new standards for efficiency and security in...

Continue Reading